Abstract: The present invention relates to pharmaceutical compositions comprising 2-{4-[N-(5,6- diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide (selexipag, NS-304, ACT-293987) which are suitable for oral administration (p.o.).
| # | Name | Date |
|---|---|---|
| 1 | 202247027353-Correspondence_Assignment_14-10-2022.pdf | 2022-10-14 |
| 1 | 202247027353.pdf | 2022-05-12 |
| 2 | 202247027353-FORM 3 [12-07-2022(online)].pdf | 2022-07-12 |
| 2 | 202247027353-STATEMENT OF UNDERTAKING (FORM 3) [12-05-2022(online)].pdf | 2022-05-12 |
| 3 | 202247027353-FORM-26 [08-07-2022(online)].pdf | 2022-07-08 |
| 3 | 202247027353-PROOF OF RIGHT [12-05-2022(online)].pdf | 2022-05-12 |
| 4 | 202247027353-COMPLETE SPECIFICATION [12-05-2022(online)].pdf | 2022-05-12 |
| 4 | 202247027353-PRIORITY DOCUMENTS [12-05-2022(online)].pdf | 2022-05-12 |
| 5 | 202247027353-FORM 1 [12-05-2022(online)].pdf | 2022-05-12 |
| 5 | 202247027353-DECLARATION OF INVENTORSHIP (FORM 5) [12-05-2022(online)].pdf | 2022-05-12 |
| 6 | 202247027353-DECLARATION OF INVENTORSHIP (FORM 5) [12-05-2022(online)].pdf | 2022-05-12 |
| 6 | 202247027353-FORM 1 [12-05-2022(online)].pdf | 2022-05-12 |
| 7 | 202247027353-COMPLETE SPECIFICATION [12-05-2022(online)].pdf | 2022-05-12 |
| 7 | 202247027353-PRIORITY DOCUMENTS [12-05-2022(online)].pdf | 2022-05-12 |
| 8 | 202247027353-FORM-26 [08-07-2022(online)].pdf | 2022-07-08 |
| 8 | 202247027353-PROOF OF RIGHT [12-05-2022(online)].pdf | 2022-05-12 |
| 9 | 202247027353-FORM 3 [12-07-2022(online)].pdf | 2022-07-12 |
| 9 | 202247027353-STATEMENT OF UNDERTAKING (FORM 3) [12-05-2022(online)].pdf | 2022-05-12 |
| 10 | 202247027353.pdf | 2022-05-12 |
| 10 | 202247027353-Correspondence_Assignment_14-10-2022.pdf | 2022-10-14 |